Magellan Health Inc (MGLN) Return on Equity ROE from the third quarter 2021 to third quarter 2020 and annually, average high and low, overall ranking from Sep 30 2021 to Sep 30 2020 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Magellan Health inc   (NASDAQ: MGLN)
    Sector • Healthcare    Industry • Healthcare Facilities
   Industry • Healthcare Facilities
   Sector • Healthcare

Magellan Health Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Magellan Health Inc in the third quarter 2021?
Magellan Health inc achieved a return on average equity (ROE) of 15.82 % in its third quarter 2021, this is above MGLN's average return on equity of 8.56%.
Magellan Health Inc shareholder's equity over the 12 months ending in its third quarter 2021 are valued at $1,909 million

ROE fell compared to the second quarter 2021, despite the net income growth of % from the second quarter 2021.

Within the Healthcare Facilities industry 14 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the second quarter 2021 from 1015 to 1189.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Sep 30 2021)
III. Quarter		 (Jun 30 2021)
II. Quarter		 (Mar 31 2021)
I. Quarter		 (Dec 31 2020)
IV. Quarter		 (Sep 30 2020)
III. Quarter
Y / Y Equity Change 22.46 % 24.68 % 33.39 % 33.78 % -
Y / Y Net Income Change -49.03 % - 52.48 % 1206.51 % -45.25 %
Net Income (TTM) in Millions 302 308 392 382 134
Return On Equity (TTM) 15.82 % 16.9 % 22.71 % 23.81 % 9.01 %
MGLN's Total Ranking # 1189 # 1015 # 593 # 451 # 1227
Equity (TTM) in Millions 1,934 1,924 1,910 1,870 1,579
Seq. Equity Change 0.52 % 0.75 % 2.12 % 18.42 % 2.35 %
Seq. Net Income Change - - -89.65 % 2209.03 % -86.05 %

Back to MGLN Management Effectiveness >> MGLN's 5 Years Annual ROE >> Compare MGLN ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 15
Sector # 113
Overall # 1189

Return On Equity Statistics
High Average Low
23.81 %
8.56 %
0.56 %
(Dec 31 2020)   (Sep 30 2019)





MGLN Annual Return On Equity (Dec 31 2020)
2020		 (Dec 31 2019)
2019		 (Dec 31 2018)
2018		 (Dec 31 2017)
2017		 (Dec 31 2016)
2016
Total Equity in Millions 1,870 1,398 1,285 1,276 1,100
Y / Y Equity Change 33.78 % 8.75 % 0.69 % 16.07 % 3.15 %
Net Income in Millions 382 56 24 110 76
Y / Y Net Income Change 583.94 % 131.18 % -78.05 % 45.33 % 164.01 %
Return On Equity 20.45 % 4 % 1.88 % 8.63 % 6.89 %

Back to MGLN Management Effectiveness >> MGLN's 5 Years Annual ROE >> Compare MGLN ROE to its Competitors




Annual Roe Comment
In 2020 ROE improved to 20.45 % compared to the previous year, due to net income growth.


More Return On Equity Ratios
Healthcare Facilities Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
MGLN's' Return on Equity at Yahoo Finance
MGLN's Roe Ratio versus Healthcare Facilities Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for MGLN's Competitors
Subscribers only: Roe for Magellan Health Inc 's Suppliers
Subscribers only: Return On Equity for MGLN's Customers




Companies with similar Return On Equity at Sep 30 2021, within Healthcare Sector ROE
3m Company  42.86 %
Talkspace Inc   40.42 %
Select Medical Holdings Corp  39.57 %
Lifevantage Corp  38.49 %
Gilead Sciences Inc   37.61 %
Organogenesis Holdings Inc   37.47 %
Encision Inc   37.27 %
Neurocrine Biosciences Inc   35.89 %
Chemed Corporation  35.36 %
Quest Diagnostics Inc  35.05 %
Elite Pharmaceuticals Inc   34.63 %
Dexcom Inc   33.65 %
Sage Therapeutics Inc   32.74 %
West Pharmaceutical Services Inc   30.94 %
Escalon Medical Corp   30.65 %
Edwards Lifesciences Corporation  29.68 %
Bionexus Gene Lab Corp   28.27 %
Pro dex Inc   27.81 %
Labcorp Holdings Inc   27.54 %
Biodelivery Sciences International Inc   27.47 %
Bruker Corporation  27.18 %
Sana Biotechnology Inc   26.99 %
Infusystem Holdings Inc  26.77 %
Johnson and Johnson  26.59 %
Amedisys Inc  25.90 %
Encompass Health Corporation  24.29 %
Agilent Technologies inc   24.18 %
Revvity Inc  23.94 %
Vertex Pharmaceuticals Inc  23.92 %
Pfizer Inc  23.83 %

Date modified: 2026-09-08T15:10:24+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.